September 15, 2026 · Phase 2 readout
NAMS Phase 2 readout: a negative outcome, -5.4%
On September 15, 2026, Obicetrapib 10mg — NewAmsterdam Pharma Co N.V. (Antioxidant Absorption) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -5.4% in the window around the event. It had already run -15.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$22.36
1d before
$21.16
Event day
$21.16
1d after
$21.16
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.3% expected); the stock actually moved -5.4%. Model confidence at the time: 200%.
See the full scored track recordPre-catalyst setup
-15.5%
30-day run-up
5513%
30-day volatility
0.8×
volume spike